Humacyte Historical Balance Sheet
| HUMA Stock | USD 4.49 0.11 2.51% |
Trend analysis of Humacyte balance sheet accounts such as Other Current Liabilities of 7.2 M or Total Current Liabilities of 15.7 M provides information on Humacyte's total assets, liabilities, and equity, which is the actual value of Humacyte to its prevalent stockholders. By breaking down trends over time using Humacyte balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Humacyte latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Humacyte is a good buy for the upcoming year.
Humacyte Inventory |
|
Humacyte |
About Humacyte Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Humacyte at a specified time, usually calculated after every quarter, six months, or one year. Humacyte Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Humacyte and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Humacyte currently owns. An asset can also be divided into two categories, current and non-current.
Humacyte Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Humacyte assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Humacyte books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Accounts Payable
An accounting item on the balance sheet that represents Humacyte obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Humacyte are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Capital Lease Obligations
Humacyte capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Humacyte asset purchases. For example, Humacyte can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Humacyte control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.Most accounts from Humacyte's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Humacyte current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.At present, Humacyte's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 7.2 M, whereas Short and Long Term Debt Total is forecasted to decline to about 45.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 48.5M | 47.8M | 58.1M | 45.9M | Total Assets | 286.5M | 204.3M | 128.2M | 196.8M |
Humacyte balance sheet Correlations
Click cells to compare fundamentals
Humacyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.